Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Skin Neoplasms | 121 | 2024 | 5860 | 11.780 |
Why?
|
Carcinoma, Squamous Cell | 90 | 2024 | 4050 | 10.580 |
Why?
|
Mohs Surgery | 29 | 2024 | 217 | 5.520 |
Why?
|
Carcinoma, Basal Cell | 21 | 2024 | 565 | 4.940 |
Why?
|
Neoplasm Staging | 35 | 2024 | 11218 | 1.980 |
Why?
|
Neoplasm Recurrence, Local | 29 | 2024 | 9407 | 1.580 |
Why?
|
Neoplasm Invasiveness | 18 | 2024 | 3610 | 1.330 |
Why?
|
Keratosis, Actinic | 5 | 2021 | 71 | 1.220 |
Why?
|
Carcinoma, Merkel Cell | 6 | 2024 | 329 | 1.170 |
Why?
|
Organ Transplantation | 7 | 2024 | 1172 | 1.040 |
Why?
|
Lymphatic Metastasis | 11 | 2020 | 2901 | 0.880 |
Why?
|
Skin | 13 | 2022 | 4499 | 0.830 |
Why?
|
Nervous System Neoplasms | 2 | 2020 | 91 | 0.820 |
Why?
|
Head and Neck Neoplasms | 6 | 2024 | 2930 | 0.800 |
Why?
|
Penile Neoplasms | 1 | 2023 | 158 | 0.780 |
Why?
|
Sentinel Lymph Node Biopsy | 5 | 2020 | 734 | 0.750 |
Why?
|
Chemoprevention | 2 | 2023 | 327 | 0.680 |
Why?
|
Keratoacanthoma | 1 | 2019 | 33 | 0.640 |
Why?
|
Retrospective Studies | 48 | 2024 | 81657 | 0.640 |
Why?
|
Bupivacaine | 1 | 2022 | 414 | 0.630 |
Why?
|
Humans | 145 | 2024 | 766812 | 0.610 |
Why?
|
Lip Neoplasms | 1 | 2018 | 36 | 0.610 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2024 | 975 | 0.610 |
Why?
|
Cohort Studies | 25 | 2024 | 41706 | 0.580 |
Why?
|
Peripheral Nerves | 2 | 2013 | 490 | 0.570 |
Why?
|
Fluorouracil | 3 | 2020 | 1652 | 0.570 |
Why?
|
Kidney Transplantation | 5 | 2024 | 4278 | 0.560 |
Why?
|
Radiotherapy, Adjuvant | 8 | 2021 | 1788 | 0.560 |
Why?
|
Death Certificates | 1 | 2018 | 172 | 0.550 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2024 | 1802 | 0.540 |
Why?
|
Nose Neoplasms | 2 | 2021 | 250 | 0.540 |
Why?
|
Sunlight | 2 | 2023 | 336 | 0.540 |
Why?
|
Prognosis | 23 | 2023 | 29959 | 0.540 |
Why?
|
Medicare | 5 | 2021 | 6813 | 0.520 |
Why?
|
Health Expenditures | 3 | 2020 | 2389 | 0.510 |
Why?
|
Aged | 53 | 2024 | 171344 | 0.500 |
Why?
|
Cause of Death | 2 | 2018 | 3717 | 0.490 |
Why?
|
Vulvar Neoplasms | 1 | 2018 | 266 | 0.490 |
Why?
|
Patient Selection | 2 | 2018 | 4252 | 0.480 |
Why?
|
Physician's Role | 2 | 2021 | 925 | 0.470 |
Why?
|
Melanoma | 8 | 2022 | 5702 | 0.470 |
Why?
|
Histiocytoma, Benign Fibrous | 1 | 2015 | 64 | 0.460 |
Why?
|
Exanthema | 1 | 2019 | 502 | 0.460 |
Why?
|
Infection Control | 2 | 2012 | 984 | 0.450 |
Why?
|
Dermatofibrosarcoma | 1 | 2014 | 49 | 0.450 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2018 | 594 | 0.440 |
Why?
|
Female | 68 | 2024 | 396532 | 0.440 |
Why?
|
Male | 62 | 2024 | 364154 | 0.430 |
Why?
|
Fellowships and Scholarships | 2 | 2023 | 1134 | 0.430 |
Why?
|
Surgical Wound Infection | 3 | 2012 | 1547 | 0.420 |
Why?
|
Aged, 80 and over | 30 | 2024 | 59548 | 0.420 |
Why?
|
Sirolimus | 2 | 2018 | 1540 | 0.400 |
Why?
|
Adrenal Cortex Hormones | 2 | 2024 | 1884 | 0.400 |
Why?
|
Middle Aged | 44 | 2024 | 223267 | 0.380 |
Why?
|
Acetamides | 2 | 2023 | 260 | 0.380 |
Why?
|
Immunocompromised Host | 3 | 2021 | 865 | 0.380 |
Why?
|
Incidence | 13 | 2024 | 21527 | 0.370 |
Why?
|
Biopsy, Needle | 4 | 2019 | 1615 | 0.370 |
Why?
|
Physicians, Primary Care | 1 | 2018 | 622 | 0.370 |
Why?
|
Sunburn | 1 | 2012 | 156 | 0.370 |
Why?
|
Medical Oncology | 4 | 2023 | 2340 | 0.360 |
Why?
|
Surgical Flaps | 3 | 2021 | 1680 | 0.360 |
Why?
|
Keratinocytes | 5 | 2022 | 876 | 0.350 |
Why?
|
Health Care Costs | 3 | 2019 | 3240 | 0.340 |
Why?
|
Disease-Free Survival | 7 | 2023 | 6853 | 0.340 |
Why?
|
Leg | 1 | 2015 | 1087 | 0.330 |
Why?
|
Pancreas Transplantation | 1 | 2010 | 194 | 0.330 |
Why?
|
Subcutaneous Fat | 1 | 2013 | 401 | 0.320 |
Why?
|
Patient Satisfaction | 2 | 2017 | 3485 | 0.290 |
Why?
|
Antineoplastic Agents | 5 | 2023 | 13644 | 0.280 |
Why?
|
Early Detection of Cancer | 2 | 2019 | 3235 | 0.280 |
Why?
|
Graft Rejection | 1 | 2020 | 4504 | 0.270 |
Why?
|
Risk Factors | 20 | 2024 | 74889 | 0.270 |
Why?
|
Immunosuppressive Agents | 2 | 2018 | 4215 | 0.270 |
Why?
|
Risk Assessment | 10 | 2022 | 24299 | 0.270 |
Why?
|
Academic Medical Centers | 4 | 2018 | 2783 | 0.260 |
Why?
|
Dermatology | 5 | 2020 | 905 | 0.260 |
Why?
|
Survival Analysis | 6 | 2020 | 10101 | 0.260 |
Why?
|
Health Behavior | 2 | 2021 | 2649 | 0.260 |
Why?
|
United States | 23 | 2024 | 72945 | 0.250 |
Why?
|
Skin Diseases, Vascular | 1 | 2005 | 41 | 0.240 |
Why?
|
Acitretin | 2 | 2023 | 16 | 0.240 |
Why?
|
Treatment Outcome | 17 | 2024 | 65286 | 0.230 |
Why?
|
Niacinamide | 2 | 2023 | 419 | 0.230 |
Why?
|
Frozen Sections | 2 | 2024 | 153 | 0.230 |
Why?
|
Aminoquinolines | 2 | 2018 | 105 | 0.230 |
Why?
|
Disease Progression | 3 | 2020 | 13642 | 0.230 |
Why?
|
Insurance Claim Review | 2 | 2019 | 744 | 0.220 |
Why?
|
Immunotherapy | 6 | 2024 | 4747 | 0.220 |
Why?
|
Facial Neoplasms | 2 | 2016 | 126 | 0.210 |
Why?
|
Laser Therapy | 3 | 2005 | 1108 | 0.210 |
Why?
|
Erythema | 1 | 2004 | 261 | 0.210 |
Why?
|
Skin Aging | 1 | 2004 | 140 | 0.210 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2018 | 646 | 0.210 |
Why?
|
Antibiotic Prophylaxis | 2 | 2010 | 641 | 0.210 |
Why?
|
Follow-Up Studies | 11 | 2021 | 39312 | 0.210 |
Why?
|
Neoplasms, Adnexal and Skin Appendage | 1 | 2023 | 26 | 0.210 |
Why?
|
Adult | 26 | 2024 | 223305 | 0.200 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2014 | 1642 | 0.200 |
Why?
|
Neoplasm Metastasis | 4 | 2021 | 4892 | 0.200 |
Why?
|
Eyelid Neoplasms | 1 | 2023 | 88 | 0.200 |
Why?
|
Practice Guidelines as Topic | 4 | 2024 | 7430 | 0.200 |
Why?
|
Neoplasms, Second Primary | 2 | 2020 | 1062 | 0.200 |
Why?
|
Societies, Medical | 2 | 2018 | 3957 | 0.190 |
Why?
|
Injections, Intralesional | 2 | 2020 | 280 | 0.190 |
Why?
|
Tranexamic Acid | 1 | 2024 | 174 | 0.190 |
Why?
|
Pamphlets | 1 | 2021 | 71 | 0.180 |
Why?
|
Keratolytic Agents | 1 | 2021 | 34 | 0.180 |
Why?
|
Antifibrinolytic Agents | 1 | 2024 | 289 | 0.180 |
Why?
|
Internship and Residency | 1 | 2021 | 5943 | 0.180 |
Why?
|
Tumor Burden | 2 | 2019 | 1902 | 0.180 |
Why?
|
Massachusetts | 3 | 2018 | 8890 | 0.180 |
Why?
|
Motor Activity | 1 | 2010 | 2711 | 0.180 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 11876 | 0.170 |
Why?
|
Postoperative Hemorrhage | 1 | 2024 | 418 | 0.170 |
Why?
|
Administration, Cutaneous | 2 | 2020 | 712 | 0.160 |
Why?
|
Kaplan-Meier Estimate | 4 | 2020 | 6514 | 0.160 |
Why?
|
Quality of Life | 3 | 2022 | 13476 | 0.160 |
Why?
|
Immunohistochemistry | 3 | 2019 | 11062 | 0.160 |
Why?
|
Dioxygenases | 1 | 2021 | 355 | 0.160 |
Why?
|
Endocarditis, Bacterial | 1 | 2003 | 436 | 0.160 |
Why?
|
Methylprednisolone | 1 | 2020 | 387 | 0.160 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2019 | 190 | 0.150 |
Why?
|
Boston | 3 | 2019 | 9346 | 0.150 |
Why?
|
Biopsy | 4 | 2024 | 6779 | 0.150 |
Why?
|
Mouth Neoplasms | 1 | 2023 | 597 | 0.150 |
Why?
|
Liver Transplantation | 1 | 2010 | 2416 | 0.150 |
Why?
|
Drug Administration Schedule | 3 | 2024 | 4853 | 0.150 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2019 | 322 | 0.150 |
Why?
|
Sensitivity and Specificity | 5 | 2019 | 14653 | 0.150 |
Why?
|
Skin Transplantation | 2 | 2021 | 1097 | 0.150 |
Why?
|
Photochemotherapy | 3 | 2020 | 828 | 0.140 |
Why?
|
Carboplatin | 1 | 2020 | 790 | 0.140 |
Why?
|
Molecular Targeted Therapy | 2 | 2019 | 2823 | 0.140 |
Why?
|
Cryotherapy | 1 | 2017 | 164 | 0.140 |
Why?
|
False Negative Reactions | 1 | 2018 | 570 | 0.140 |
Why?
|
Preoperative Period | 1 | 2019 | 564 | 0.130 |
Why?
|
Lymph Nodes | 2 | 2018 | 3468 | 0.130 |
Why?
|
Lip | 1 | 2018 | 196 | 0.130 |
Why?
|
Aftercare | 2 | 2019 | 915 | 0.130 |
Why?
|
Collagen | 1 | 2004 | 2635 | 0.130 |
Why?
|
Survival Rate | 3 | 2020 | 12826 | 0.130 |
Why?
|
Curettage | 1 | 2016 | 74 | 0.130 |
Why?
|
Multivariate Analysis | 3 | 2014 | 12064 | 0.130 |
Why?
|
Psoriasis | 1 | 2023 | 925 | 0.130 |
Why?
|
Prednisone | 1 | 2020 | 1566 | 0.120 |
Why?
|
Anesthetics, Local | 1 | 2022 | 1005 | 0.120 |
Why?
|
Lymphatic Vessels | 1 | 2019 | 356 | 0.120 |
Why?
|
Cancer Care Facilities | 1 | 2018 | 428 | 0.120 |
Why?
|
Delphi Technique | 2 | 2021 | 892 | 0.120 |
Why?
|
Medicare Part D | 1 | 2020 | 355 | 0.120 |
Why?
|
Epidermis | 1 | 2017 | 539 | 0.120 |
Why?
|
Observer Variation | 1 | 2021 | 2614 | 0.120 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 904 | 0.120 |
Why?
|
Salvage Therapy | 1 | 2021 | 1274 | 0.120 |
Why?
|
Cisplatin | 1 | 2020 | 1656 | 0.110 |
Why?
|
Guideline Adherence | 1 | 2024 | 2233 | 0.110 |
Why?
|
Patient Education as Topic | 2 | 2021 | 2334 | 0.110 |
Why?
|
Blood Vessels | 1 | 2019 | 1111 | 0.110 |
Why?
|
Hospitals | 3 | 2023 | 3885 | 0.110 |
Why?
|
DNA-Binding Proteins | 3 | 2021 | 9613 | 0.110 |
Why?
|
Single-Blind Method | 2 | 2009 | 1587 | 0.110 |
Why?
|
Reproducibility of Results | 3 | 2021 | 20146 | 0.110 |
Why?
|
Statistics, Nonparametric | 1 | 2019 | 2846 | 0.110 |
Why?
|
Medicine | 1 | 2021 | 944 | 0.110 |
Why?
|
Diagnosis, Differential | 2 | 2019 | 12985 | 0.110 |
Why?
|
Transplantation, Homologous | 1 | 2022 | 4860 | 0.100 |
Why?
|
Sex Factors | 4 | 2024 | 10619 | 0.100 |
Why?
|
Scalp | 1 | 2016 | 390 | 0.100 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2020 | 10745 | 0.100 |
Why?
|
Pyrazoles | 1 | 2023 | 2030 | 0.100 |
Why?
|
Databases, Factual | 2 | 2019 | 8065 | 0.100 |
Why?
|
Neoadjuvant Therapy | 1 | 2024 | 2902 | 0.100 |
Why?
|
Combined Modality Therapy | 3 | 2020 | 8540 | 0.100 |
Why?
|
Prescription Drugs | 1 | 2020 | 634 | 0.100 |
Why?
|
Eccrine Porocarcinoma | 1 | 2012 | 18 | 0.100 |
Why?
|
Sex Distribution | 1 | 2017 | 2274 | 0.100 |
Why?
|
Fibrosarcoma | 1 | 2014 | 313 | 0.100 |
Why?
|
Disease Susceptibility | 1 | 2019 | 1791 | 0.100 |
Why?
|
Brachytherapy | 1 | 2019 | 1221 | 0.100 |
Why?
|
Esthetics | 1 | 2013 | 328 | 0.100 |
Why?
|
Disease Management | 2 | 2021 | 2533 | 0.100 |
Why?
|
Extremities | 1 | 2017 | 869 | 0.100 |
Why?
|
Pain, Postoperative | 1 | 2022 | 1768 | 0.100 |
Why?
|
Prospective Studies | 7 | 2024 | 54872 | 0.100 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2016 | 2902 | 0.090 |
Why?
|
Sarcoma | 1 | 2022 | 1802 | 0.090 |
Why?
|
Sweat Gland Neoplasms | 1 | 2012 | 111 | 0.090 |
Why?
|
Comorbidity | 3 | 2020 | 10580 | 0.090 |
Why?
|
Proportional Hazards Models | 2 | 2016 | 12536 | 0.090 |
Why?
|
Skin Pigmentation | 3 | 2020 | 278 | 0.090 |
Why?
|
Veterans | 2 | 2021 | 2667 | 0.090 |
Why?
|
Predictive Value of Tests | 3 | 2020 | 15425 | 0.090 |
Why?
|
E-Selectin | 1 | 2012 | 576 | 0.090 |
Why?
|
Suntan | 1 | 2009 | 17 | 0.080 |
Why?
|
Carcinoma | 1 | 2021 | 2325 | 0.080 |
Why?
|
Reoperation | 2 | 2020 | 4325 | 0.080 |
Why?
|
Patient Care Team | 1 | 2021 | 2519 | 0.080 |
Why?
|
Sterilization | 1 | 2010 | 132 | 0.080 |
Why?
|
Epithelial Cells | 1 | 2021 | 3698 | 0.080 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2018 | 3552 | 0.080 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2023 | 2429 | 0.080 |
Why?
|
Evidence-Based Medicine | 2 | 2020 | 3692 | 0.080 |
Why?
|
Analysis of Variance | 2 | 2014 | 6214 | 0.080 |
Why?
|
Confidence Intervals | 1 | 2014 | 2921 | 0.080 |
Why?
|
Arthritis, Rheumatoid | 1 | 2023 | 3788 | 0.070 |
Why?
|
Physician-Patient Relations | 1 | 2021 | 3266 | 0.070 |
Why?
|
Germany | 2 | 2020 | 882 | 0.070 |
Why?
|
Myeloid Cells | 1 | 2012 | 838 | 0.070 |
Why?
|
Pain | 1 | 2022 | 5098 | 0.070 |
Why?
|
Ultraviolet Rays | 3 | 2020 | 1100 | 0.070 |
Why?
|
Cross-Sectional Studies | 5 | 2023 | 26309 | 0.070 |
Why?
|
Age Factors | 3 | 2020 | 18397 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 1 | 2023 | 5690 | 0.070 |
Why?
|
Epigenesis, Genetic | 1 | 2020 | 3828 | 0.070 |
Why?
|
Hospital Costs | 1 | 2012 | 955 | 0.060 |
Why?
|
Analgesics, Opioid | 1 | 2022 | 3837 | 0.060 |
Why?
|
Australia | 2 | 2020 | 1263 | 0.060 |
Why?
|
Neoplasms | 2 | 2016 | 22350 | 0.060 |
Why?
|
Antibodies, Monoclonal | 2 | 2024 | 9244 | 0.060 |
Why?
|
Clinical Trials as Topic | 2 | 2020 | 8045 | 0.060 |
Why?
|
Fibrillar Collagens | 1 | 2004 | 42 | 0.060 |
Why?
|
Carcinoma in Situ | 2 | 2016 | 784 | 0.060 |
Why?
|
Attitude | 1 | 2009 | 768 | 0.060 |
Why?
|
Case-Control Studies | 2 | 2019 | 22248 | 0.060 |
Why?
|
Causality | 1 | 2010 | 1252 | 0.060 |
Why?
|
Consensus | 1 | 2014 | 3208 | 0.060 |
Why?
|
Gene Expression Profiling | 1 | 2020 | 9528 | 0.060 |
Why?
|
Keratosis | 1 | 2004 | 81 | 0.060 |
Why?
|
Mass Screening | 1 | 2019 | 5454 | 0.050 |
Why?
|
Socioeconomic Factors | 1 | 2017 | 7841 | 0.050 |
Why?
|
Risk | 1 | 2015 | 9602 | 0.050 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2004 | 95 | 0.050 |
Why?
|
Nitric Oxide | 1 | 2012 | 2140 | 0.050 |
Why?
|
Interviews as Topic | 1 | 2010 | 2741 | 0.050 |
Why?
|
Injections, Subcutaneous | 1 | 2024 | 684 | 0.050 |
Why?
|
Psychometrics | 1 | 2012 | 3060 | 0.050 |
Why?
|
src-Family Kinases | 1 | 2004 | 539 | 0.050 |
Why?
|
Epidermal Growth Factor | 1 | 2004 | 697 | 0.050 |
Why?
|
Registries | 1 | 2018 | 8352 | 0.050 |
Why?
|
Private Practice | 1 | 2022 | 154 | 0.050 |
Why?
|
Data Collection | 1 | 2010 | 3321 | 0.050 |
Why?
|
Microscopy, Electron | 1 | 2004 | 2551 | 0.050 |
Why?
|
5-Methylcytosine | 1 | 2021 | 147 | 0.050 |
Why?
|
Severity of Illness Index | 1 | 2019 | 15912 | 0.050 |
Why?
|
Interferon-gamma | 1 | 2009 | 3157 | 0.040 |
Why?
|
Transcription Factors | 2 | 2019 | 12159 | 0.040 |
Why?
|
Protective Clothing | 1 | 2021 | 103 | 0.040 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 2 | 2013 | 897 | 0.040 |
Why?
|
Hutchinson's Melanotic Freckle | 1 | 2020 | 26 | 0.040 |
Why?
|
Sunscreening Agents | 1 | 2021 | 138 | 0.040 |
Why?
|
Population Surveillance | 1 | 2010 | 2594 | 0.040 |
Why?
|
Drug Dosage Calculations | 1 | 2020 | 116 | 0.040 |
Why?
|
Uncertainty | 1 | 2024 | 765 | 0.040 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2013 | 3114 | 0.040 |
Why?
|
Cicatrix | 1 | 2005 | 798 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2019 | 20710 | 0.040 |
Why?
|
Algorithms | 1 | 2019 | 14073 | 0.040 |
Why?
|
Calcitriol | 1 | 2020 | 301 | 0.040 |
Why?
|
T-Lymphocytes | 2 | 2013 | 10263 | 0.040 |
Why?
|
Physical Examination | 1 | 2024 | 1265 | 0.040 |
Why?
|
Referral and Consultation | 1 | 2010 | 3618 | 0.040 |
Why?
|
Europe | 1 | 2024 | 3430 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2019 | 18076 | 0.030 |
Why?
|
Cell Division | 2 | 2009 | 4473 | 0.030 |
Why?
|
Histocytochemistry | 1 | 1997 | 697 | 0.030 |
Why?
|
Tissue Expansion | 1 | 1997 | 163 | 0.030 |
Why?
|
Educational Status | 1 | 2023 | 2510 | 0.030 |
Why?
|
Drug Synergism | 1 | 2020 | 1757 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 3 | 2019 | 36570 | 0.030 |
Why?
|
Cell Size | 1 | 1997 | 625 | 0.030 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2009 | 4652 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2020 | 2228 | 0.030 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 1997 | 482 | 0.030 |
Why?
|
Young Adult | 2 | 2019 | 59939 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 2021 | 1667 | 0.030 |
Why?
|
Cryosurgery | 1 | 2020 | 479 | 0.030 |
Why?
|
Dinoprostone | 1 | 1997 | 597 | 0.030 |
Why?
|
Drugs, Generic | 1 | 2020 | 457 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2021 | 2425 | 0.030 |
Why?
|
Cyclic AMP Response Element-Binding Protein | 1 | 2016 | 501 | 0.030 |
Why?
|
Cyclic AMP | 1 | 1997 | 1472 | 0.030 |
Why?
|
Proto-Oncogene Proteins | 2 | 2021 | 4523 | 0.030 |
Why?
|
Cells, Cultured | 3 | 2013 | 18986 | 0.030 |
Why?
|
Geriatric Assessment | 1 | 2020 | 1422 | 0.030 |
Why?
|
Nitroarginine | 1 | 2012 | 66 | 0.030 |
Why?
|
Stress, Mechanical | 1 | 1997 | 1674 | 0.030 |
Why?
|
Cell Proliferation | 3 | 2016 | 10451 | 0.020 |
Why?
|
Interleukin-15 | 1 | 2013 | 186 | 0.020 |
Why?
|
Arginase | 1 | 2012 | 81 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2021 | 2841 | 0.020 |
Why?
|
Wound Closure Techniques | 1 | 2012 | 88 | 0.020 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2013 | 306 | 0.020 |
Why?
|
Time Factors | 3 | 2020 | 40149 | 0.020 |
Why?
|
Drug Costs | 1 | 2020 | 1194 | 0.020 |
Why?
|
Receptors, CCR2 | 1 | 2012 | 215 | 0.020 |
Why?
|
Education, Medical, Graduate | 1 | 2023 | 2418 | 0.020 |
Why?
|
Ultrasonography | 2 | 2018 | 5990 | 0.020 |
Why?
|
Dermis | 1 | 2012 | 203 | 0.020 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2012 | 513 | 0.020 |
Why?
|
HLA-DR Antigens | 1 | 2012 | 609 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2020 | 8623 | 0.020 |
Why?
|
Geography | 1 | 2012 | 651 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 1997 | 2629 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2019 | 2045 | 0.020 |
Why?
|
Recurrence | 1 | 2022 | 8507 | 0.020 |
Why?
|
Curriculum | 1 | 2023 | 3783 | 0.020 |
Why?
|
Medical Staff, Hospital | 1 | 2014 | 602 | 0.020 |
Why?
|
Signal Transduction | 3 | 2013 | 23618 | 0.020 |
Why?
|
Axilla | 1 | 2012 | 622 | 0.020 |
Why?
|
Lectins, C-Type | 1 | 2013 | 592 | 0.020 |
Why?
|
Body Weight | 1 | 2020 | 4626 | 0.020 |
Why?
|
Pilot Projects | 1 | 2022 | 8728 | 0.020 |
Why?
|
Pore Forming Cytotoxic Proteins | 1 | 2009 | 129 | 0.020 |
Why?
|
Perforin | 1 | 2009 | 167 | 0.020 |
Why?
|
Mortality | 1 | 2020 | 2908 | 0.020 |
Why?
|
DNA | 2 | 2004 | 7210 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2023 | 3530 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2013 | 1836 | 0.020 |
Why?
|
History, 20th Century | 2 | 2009 | 2764 | 0.020 |
Why?
|
Cell Cycle | 1 | 2016 | 2925 | 0.020 |
Why?
|
Mice, SCID | 1 | 2013 | 2626 | 0.020 |
Why?
|
Granzymes | 1 | 2009 | 278 | 0.020 |
Why?
|
DNA Methylation | 1 | 2021 | 4427 | 0.020 |
Why?
|
Biopsy, Fine-Needle | 1 | 2012 | 1131 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2019 | 3667 | 0.020 |
Why?
|
Mice | 3 | 2021 | 81898 | 0.020 |
Why?
|
Interleukin-2 | 1 | 2013 | 1895 | 0.020 |
Why?
|
Lymph Node Excision | 1 | 2012 | 1267 | 0.020 |
Why?
|
Forkhead Transcription Factors | 1 | 2013 | 1627 | 0.020 |
Why?
|
ets-Domain Protein Elk-1 | 1 | 2004 | 39 | 0.020 |
Why?
|
Patient Participation | 1 | 2014 | 1445 | 0.010 |
Why?
|
Ultraviolet Therapy | 1 | 2005 | 82 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2013 | 2391 | 0.010 |
Why?
|
Logistic Models | 1 | 2019 | 13276 | 0.010 |
Why?
|
Intermediate Filament Proteins | 1 | 2004 | 261 | 0.010 |
Why?
|
Phosphotyrosine | 1 | 2004 | 458 | 0.010 |
Why?
|
Interleukin-10 | 1 | 2009 | 1182 | 0.010 |
Why?
|
Response Elements | 1 | 2004 | 308 | 0.010 |
Why?
|
Regression Analysis | 1 | 2012 | 6329 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2004 | 478 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2020 | 10384 | 0.010 |
Why?
|
Prevalence | 1 | 2020 | 15835 | 0.010 |
Why?
|
Aminolevulinic Acid | 1 | 2004 | 147 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2014 | 5306 | 0.010 |
Why?
|
Proteins | 1 | 1997 | 6002 | 0.010 |
Why?
|
Antigens, CD | 1 | 2013 | 4033 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2012 | 3723 | 0.010 |
Why?
|
Melanocytes | 1 | 2005 | 509 | 0.010 |
Why?
|
Membrane Glycoproteins | 1 | 2012 | 3702 | 0.010 |
Why?
|
Transforming Growth Factor beta | 1 | 2009 | 1996 | 0.010 |
Why?
|
Animals | 3 | 2021 | 168939 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2016 | 17089 | 0.010 |
Why?
|
Preoperative Care | 1 | 2008 | 2253 | 0.010 |
Why?
|
Photosensitizing Agents | 1 | 2004 | 627 | 0.010 |
Why?
|
Phenotype | 1 | 1997 | 16722 | 0.010 |
Why?
|
Endothelial Cells | 1 | 2012 | 3582 | 0.010 |
Why?
|
Enzyme Activation | 1 | 2004 | 3587 | 0.010 |
Why?
|
Periodicals as Topic | 1 | 2009 | 1463 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2009 | 5502 | 0.010 |
Why?
|
Cytokines | 1 | 2013 | 7438 | 0.010 |
Why?
|
Ligands | 1 | 2004 | 3274 | 0.010 |
Why?
|
DNA Replication | 1 | 2004 | 1426 | 0.010 |
Why?
|
Clinical Competence | 1 | 2012 | 4858 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6548 | 0.010 |
Why?
|
Adolescent | 2 | 2017 | 88902 | 0.010 |
Why?
|
Mutation | 1 | 2019 | 30214 | 0.010 |
Why?
|
Phosphorylation | 1 | 2004 | 8310 | 0.010 |
Why?
|
Apoptosis | 1 | 2009 | 9514 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2004 | 7612 | 0.010 |
Why?
|
Models, Biological | 1 | 2004 | 9464 | 0.000 |
Why?
|
Cell Differentiation | 1 | 2004 | 11657 | 0.000 |
Why?
|
Gene Expression Regulation | 1 | 2004 | 11924 | 0.000 |
Why?
|